More Is Not Always Better: Intensive Glycemic Control in Type 2 Diabetes

摘要

The effects of intensive glycemic control on cardiovascular disease (CVD) outcomes in "high risk" type 2 diabetes are the subject of much debate. The New England Journal of Medicine recently published results of 2 landmark clinical trials in patients with type 2 diabetes and CVD or multiple risk factors, ACCORD (Action to Control Cardiovascular Risk in Diabetes, N = 10,521) and ADVANCE (Action in Diabetes and Cardiovascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation, N = 11.140)#